{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:49Z","timestamp":1791945949546,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Direct\u2010acting antiviral agents (DAAs) are safe and effective in eradicating hepatitis C virus (HCV) infection. Ribavirin is still used as an important part of modern HCV therapy. Main protein involved in ribavirin cellular uptake is encoded by solute carrier family 29, member1 (SLC29A1), which has a role in ribavirin uptake into erythrocytes. To evaluate the association of SLC29 Agene polymorphism (rs760370) with hematological changes and sustained virological response (SVR) in Egyptian chronic HCV patients treated with DAAs. Sixty chronic HCV infected patients receiving DAAs with ribavirin (group I; triple therapy) were classified as group Ia is associated with hematologic complication, group Ib without complications. Sixty chronic HCV infected patients receiving DAAs without ribavirin were included in (group II; dual therapy). Liver tests, complete blood counts, hemolytic markers (indirect bilirubin, reticulocytic count and LDH), HCV RNA level and SLC29A1 (rs760370) using allelic discrimination real time PCR were done for all subjects. Median age of the enrolled patients was 37 years old with female majority (69 patients). Patients carrying GG genotype had increased a significant risk of hemoglobin decline \u2265\u20092\u2009g\/dL as compared to AA genotype. Similar results were obtained in the dominant model which also had increased risk for Hb decline (OR\u2009=\u20094.26, 95% CI: 1.34\u201313.55, and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011), changes in reticulocyte count and platelet count (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.022, and 0.020 respectively). Also, patients with dominant genetic models had an increase in SVR in patients receiving triple therapy. Regarding the change in hematological parameters revealed a highly significant decrease in delta \u0394 Hb, RBCs count and MCHC (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) in group 1 compared to group 2 plus a statistically significant increase in delta \u0394 AST level, indirect bilirubin and LDH in group 1 compared to group 2\n                    <jats:italic>p<\/jats:italic>\n                    \u2010value (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) respectively. SNP rs760370A\u2009&gt;\u2009G at SLC29A1 gene influences the severity of ribavirin\u2010induced anemia, possibly mirroring erythrocyte uptake of ribavirin and that increases SVR in chronic hepatitis C patients receiving DAAs and ribavirin.\n                  <\/jats:p>","DOI":"10.1002\/jmv.70692","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:24:38Z","timestamp":1763126678000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Solute Carrier Gene Polymorphism (SLC29A1) in Relation to Treatment Outcome and Hematological Changes in Chronic Hepatitis C Patients Treated With Direct Acting Antivirals Plus Ribavirin"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8970-0286","authenticated-orcid":false,"given":"Mohamed","family":"Abdel\u2010Samiee","sequence":"first","affiliation":[{"name":"Departement of Hepatology and Gastroenterology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Aburaia","sequence":"additional","affiliation":[{"name":"Departement of Clinical Pathology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-7164","authenticated-orcid":false,"given":"Eman","family":"Abdelsameea","sequence":"additional","affiliation":[{"name":"Departement of Hepatology and Gastroenterology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fathy","sequence":"additional","affiliation":[{"name":"Departement of Clinical Pathology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elshaarawy","sequence":"additional","affiliation":[{"name":"Departement of Hepatology and Gastroenterology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan M.","family":"Bedair","sequence":"additional","affiliation":[{"name":"Departement of Clinical Pathology, National Liver Institute Menoufia University Shebin El\u2010Kom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13186"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010024\u201001432\u2010x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02280-08"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i2.123"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439\u2010019\u201002081\u2010x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.145854"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/656334"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834dd7e2"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.12.038"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00064-3"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5789"},{"issue":"2","key":"e_1_2_11_13_1","first-page":"882","article-title":"Genotyping of Single Nucleotide Polymorphisms by 5\u2032 Nuclease Allelic Discrimination Methods","volume":"2","author":"Mari M.","year":"2012","journal-title":"MolBiol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0118-x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i5.784"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12423"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku519"},{"key":"e_1_2_11_18_1","article-title":"The Effect of Genetic Variations on Ribavirin Pharmacokinetics and Treatment Response in HCV\u20104 Egyptian Patients Receiving Sofosbuvir\/Daclatasvir and Ribavirin","volume":"121","author":"Abdelkawya K. S.","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2021.138116"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08825"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.011"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02727.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13290"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.09.008"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.70692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:18:11Z","timestamp":1791944291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.70692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/jmv.70692"],"URL":"https:\/\/doi.org\/10.1002\/jmv.70692","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70692"}}